Fig. 2: VHHs binding on cells expressing hACE2. | Nature Communications

Fig. 2: VHHs binding on cells expressing hACE2.

From: Targeting ACE2 with a camelid antibody inhibits SARS-CoV-2 binding and has protective effects in vivo

Fig. 2: VHHs binding on cells expressing hACE2.The alternative text for this image may have been generated using AI.

Cells were incubated with the different VHHs (10 µg/mL), stained with an anti-myc antibody and a AF488-conjugated anti-mouse antibody, before being analyzed by flow cytometry. a B07, B09, B10 binding efficacy on HEK293-hACE2-expressing cells. Data are means ± SD of three independent experiments. Parental HEK293 cells were used as control. b B07, B09, B10 binding efficacy on cells expressing endogenous hACE2 (IGROV-1). Anti-IgE VHH was used as a control (ctl). Data are means ± SD, n = 6 (ctl, B07) or 3 (B09, B10) independent experiments. c Fluorescence diagram overlays: B07, B09, B10 efficacy on cells expressing exogenous (HEK293-hACE2) or endogenous hACE2 (IGROV-1). Background (blue) corresponds to the fluorescence intensity obtained on parental cells (HEK293) or using a VHH control (anti-IgE VHH) (IGROV-1). Source Data are provided as a Source Data file.

Back to article page